FDA guidance details how to develop REMS assessment plans

When designing REMS programs, drug companies should simultaneously develop a plan for assessing the program's effectiveness in meeting its risk mitigation goals, according to new draft guidance FDA released

Read the full 297 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE